Fact CheckerSign in

NCT06572852Recruiting

Next-Generation Endometriosis Diagnostics Through Comprehensive Multi-Dimensional Analysis

Source: ClinicalTrials.gov · Last updated 7 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

This study is a multicentric, observational, case-control, non-profit with additional procedures. It aims to deepen the understanding of the chronic gynecological conditions of endometriosis and adenomyosis, which significantly impact women's reproductive health. Its purpose is to improve early diagnosis and personalized treatment of these conditions using a multi-omic approach, that integrates genetic, epigenetic, imaging, and endometrial receptivity data. The goal is also to refine image-based predictions through recent advancements in artificial intelligence and to study uterine extracellular vesicles to assess fertility non-invasively. The study targets patients with endometriosis and/or adenomyosis and involves women seeking fertility treatments at assisted reproduction centers, who will serve as a control population. The study comprises both prospective and retrospective components. The prospective recruitment involves the collection of blood and uterine fluid samples, while the retrospective element utilizes pre-existing biobank samples for comprehensive genetic and epigenetic analysis.

Status (registry)
Recruiting
Study type
Observational
Enrollment
530 (estimated)
First submitted
23 Aug 2024
Start date
7 Nov 2024
Primary completion date
28 Feb 2026
Lead sponsor
IRCCS San Raffaele
NCT number
NCT06572852

What you commit to

  • Study type: Observational
  • Planned participants: 530
  • From 7 Nov 2024 to the primary completion date, 28 Feb 2026
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Patients unable or unwilling to sign the informed consent
  • Individuals who exhibit the presence of sactosalpinx or other uterine pathologies such as fibroids, polyps, or irregular endometrial thickening will be excluded from participation in this study.
    • These exclusion criteria are applicable across all groups to ensure the accuracy and reliability of the study's findings related to endometriosis and adenomyosis.

Who the study is looking for

  • Participants eligible for cases with endometriosis and adenomyosis, must meet the following criteria:
  • Able to give informed consent for participation in the study.
  • European descent.
  • Confirmed diagnosis of both endometriosis and adenomyosis through ultrasound screening.
  • Listed for assisted reproductive treatment, specifically within their first or second IVF cycle.
    • Participants eligible for cases with only endometriosis must meet the following criteria:
  • Able to give informed consent for participation in the study.
  • European descent.
  • Confirmed diagnosis of endometriosis with no ultrasound evidence of adenomyosis.
  • Enrolled in an assisted reproductive treatment cycle involving embryo thawing.
    • Participants eligible for cases with only adenomyosis must meet the following criteria:
  • Able to give informed consent for participation in the study.
  • European descent.
  • Confirmed diagnosis of adenomyosis with no ultrasound evidence of endometriosis.
  • Enrolled in an assisted reproductive treatment cycle involving embryo thawing.
    • Participants eligible as controls must meet the following criteria:
  • Able to give informed consent for participation in the study.
  • European descent.
  • Undergone ultrasound screenings that have excluded the presence of endometriosis or adenomyosis.
  • Listed for assisted reproductive treatment, specifically within their first or second IVF cycle.
  • Presence of reduced ovarian reserve or non-severe male factor infertility.

Age in the registry: 18 years to 40 years · Sex: Female · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Azienda Ospedaliero- Universitaria "Renato Dulbecco" di Catanzaro
Coordinator of this site? Confirm its status
CatanzaroItalyActive, not recruiting
IRCCS San Raffaele Hospital
Coordinator of this site? Confirm its status
MilanItalyRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.